Welcome to our dedicated page for Bitwise MARA Option Income Strategy ETF news (Ticker: IMRA), a resource for investors and traders seeking the latest updates and insights on Bitwise MARA Option Income Strategy ETF stock.
Bitwise MARA Option Income Strategy ETF (IMRA) reports fund updates tied to monthly distributions for Bitwise's Option Income Strategy ETF suite. News for the fund centers on distribution per share, distribution rate, 30-day SEC yield, payment dates, return of capital treatment, expenses, and performance periods.
Fund updates also describe risks associated with the option-income approach, including derivative instruments, leverage, issuer-specific volatility, and differences between derivatives and direct holdings of traditional securities.
Imara Inc. (Nasdaq: IMRA) will host a conference call on May 11, 2021, at 8:30 a.m. ET to discuss its Q1 2021 financial results and recent business highlights. The call will be accessible through a live webcast on the company’s website. Imara is focused on developing therapies for rare genetic disorders affecting hemoglobin, with its lead candidate, IMR-687, targeting conditions such as sickle cell disease and beta-thalassemia. IMR-687 is a potent oral treatment designed to modify disease mechanisms.
Summary not available.
Imara Inc. (Nasdaq: IMRA) announced that independent data monitoring committees endorsed the opening of higher dose treatment arms for their IMR-687 clinical trials targeting sickle cell disease and beta-thalassemia. The higher dose arms were pre-specified in the trial protocols, allowing for doses of 300 mg or 400 mg based on patient weight. Initial dosing in the Phase 2a trial began as low as 50 mg daily. Preliminary data from these enhanced dosing arms is expected in the latter half of 2021, following recommendations from the safety review committee for dosage escalation in the ongoing Phase 2a trial.
Imara Inc. (Nasdaq: IMRA) announced significant advancements in the development of IMR-687, an oral treatment for sickle cell disease and beta-thalassemia. The company reported financial results for 2020, with a net loss of $49.2 million. IMR-687 is progressing through Phase 2b trials, with promising data from a Phase 2a trial indicating well-tolerated results and reduced vaso-occlusive crises. The company has raised $86.5 million in its IPO and expects research and development expenses between $50 million and $55 million in 2021. The leadership team has also expanded, enhancing operational capacity.
Imara Inc. (Nasdaq: IMRA) will host a conference call and webcast on March 5, 2021, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2020. The call aims to provide insights into recent business developments and offers investors an opportunity to understand the company's progress. Imara is focused on developing IMR-687, a promising treatment for sickle cell disease and beta-thalassemia.
Imara Inc. (Nasdaq: IMRA) announced that CEO Rahul Ballal, Ph.D., will participate in a Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, from 1:40-2:10 p.m. ET. This clinical-stage biotechnology company focuses on developing therapeutics for rare inherited genetic disorders of hemoglobin, particularly with its investigational drug IMR-687. A replay of the chat will be available on Imara's website under the 'Events and Presentations' section.
Imara Inc. has appointed Kenneth Attie, M.D., as Senior Vice President and Chief Medical Officer. Dr. Attie brings over 30 years of experience in the biopharmaceutical industry, notably from Acceleron Pharma, where he led clinical development for therapies approved for rare anemias. His leadership is expected to enhance the development of IMR-687, a treatment targeting hemoglobin disorders. IMR-687 is designed to be a disease-modifying oral therapy for sickle cell disease and beta-thalassemia, potentially improving patient outcomes significantly.
Imara Inc. (Nasdaq: IMRA) reported promising results from its Phase 2a clinical trial of IMR-687 for treating sickle cell disease (SCD). Patients treated with IMR-687 experienced a 25% reduction in vaso-occlusive crises compared to placebo. Biomarker data showed significant improvements in markers of hemolysis and inflammation. IMR-687 was well tolerated, with no serious adverse effects noted. Future updates from the ongoing studies, including the Phase 2a open label extension and Phase 2b trials, are expected in 2021, indicating a strong focus on advancing the treatment.
Imara Inc. (Nasdaq: IMRA) presented preliminary data from its ongoing Phase 2a open label extension trial for IMR-687, an investigational treatment for sickle cell disease (SCD). Case reports showed increased HbF percentage and F-cell counts after six months of treatment. Improvements in clinical outcomes and biomarkers were also noted. IMR-687 was well tolerated when used alone or with hydroxyurea. Two patients reported significant reductions in vaso-occlusive crises (VOCs), with one experiencing a 55% decrease. The company plans to report further data in Q1 2021.
Imara Inc. (Nasdaq: IMRA) announced the presentation of clinical data from its ongoing IMR-687 Phase 2a clinical trial at the virtual American Society of Hematology Annual Meeting on December 5-8, 2020. The presentation, focusing on the benefits and safety of long-term use of IMR-687 in adult sickle cell patients, is scheduled for on-demand viewing on December 6. Imara completed dosing in the Phase 2a clinical trial in Q3 2020 and plans to report top-line data by late Q4 2020, with additional data expected in Q1 2021.